| Trial ID: | L1668 |
| Source ID: | NCT03596749
|
| Associated Drug: |
Sevelamer Carbonate
|
| Title: |
The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
CKD Stage 3b|CKD Stage 4
|
| Interventions: |
DRUG: Sevelamer Carbonate
|
| Outcome Measures: |
Primary: Difference in the serum concentration of TMAO between treatment group and control group, The serum concentration of TMAO will be evaluated by high performance liquid chromatography (HPLC), 22 weeks | Secondary: Difference in the serum concentration of p-cresyl sulfate between treatment group and control group, The serum concentration of p-cresyl sulfate will be evaluated by high performance liquid chromatography (HPLC), 22 weeks|Difference in the serum concentration of indoxyl sulfate between treatment group and control group, The serum concentration of indoxyl sulfate will be evaluated by high performance liquid chromatography (HPLC), 22 weeks|Difference in the serum concentration of LDL-C between treatment group and control group, Chemistry evaluations, 22 weeks|Difference in the serum concentration of uric acid between treatment group and control group, Chemistry evaluations, 22 weeks
|
| Sponsor/Collaborators: |
Sponsor: Fan Fan Hou
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2018-09-01
|
| Completion Date: |
2019-07-01
|
| Results First Posted: |
|
| Last Update Posted: |
2018-08-07
|
| Locations: |
Renal Division, Nanfang Hospital,Southern Medical University, Guangzhou, Guangdong, 510515, China
|
| URL: |
https://clinicaltrials.gov/show/NCT03596749
|
